ANVS

Company Overview — What Does Annovis Bio, Inc. Do?

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania. Annovis Bio, Inc. (ANVS) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Maria-Luisa Maccecchini and employs approximately 3 people. With a market capitalization of $60M, ANVS is one of the notable companies in the Healthcare sector.

Annovis Bio, Inc. (ANVS) Stock Rating — Avoid (April 2026)

As of April 2026, Annovis Bio, Inc. receives a Avoid rating with a composite score of 28.5/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.ANVS ranks #4,021 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Annovis Bio, Inc. ranks #698 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ANVS Stock Price and 52-Week Range

Annovis Bio, Inc. (ANVS) currently trades at $1.62. The 52-week high for ANVS is $5.50, which means the stock is currently trading -70.5% from its annual peak. The 52-week low is $1.11, putting the stock 45.9% above its annual trough. Recent trading volume was 2.6M shares, reflecting moderate market activity.

Is ANVS Overvalued or Undervalued? — Valuation Analysis

Annovis Bio, Inc. (ANVS) carries a value factor score of 14/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 3.82x, versus the sector average of 2.75x.

At current multiples, Annovis Bio, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Annovis Bio, Inc. Profitability — ROE, Margins, and Quality Score

Annovis Bio, Inc. (ANVS) earns a quality factor score of 16/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -187.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -150.2% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ANVS Debt, Balance Sheet, and Financial Health

Annovis Bio, Inc. has a debt-to-equity ratio of 25.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 5.80x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $15M.

ANVS has a beta of 1.45, meaning it is more volatile than the broader market — a $10,000 investment in ANVS would be expected to move 45.3% more than the S&P 500 on any given day. The stability factor score for Annovis Bio, Inc. is 22/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Annovis Bio, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Annovis Bio, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.40. Net income for the quarter was $-32M. Operating income came in at $-24M.

In FY 2025, Annovis Bio, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.40. Net income for the quarter was $-29M. Operating income came in at $-30M.

In Q3 2025, Annovis Bio, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.37. Net income for the quarter was $-7M. Operating income came in at $-7M.

In Q2 2025, Annovis Bio, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.32. Net income for the quarter was $-6M. Operating income came in at $-6M.

Over the past 8 quarters, Annovis Bio, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing ANVS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ANVS Dividend Yield and Income Analysis

Annovis Bio, Inc. (ANVS) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ANVS Momentum and Technical Analysis Profile

Annovis Bio, Inc. (ANVS) has a momentum factor score of 48/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 48/100 reflects moderate short selling activity.

ANVS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Annovis Bio, Inc. (ANVS) ranks #698 out of 838 stocks based on the Blank Capital composite score. This places ANVS in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ANVS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ANVS vs S&P 500 (SPY) comparison to assess how Annovis Bio, Inc. stacks up against the broader market across all factor dimensions.

ANVS Next Earnings Date

No upcoming earnings date has been announced for Annovis Bio, Inc. (ANVS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ANVS? — Investment Thesis Summary

The quantitative profile for Annovis Bio, Inc. suggests caution. The quality score of 16/100 flags below-average profitability. The value score of 14/100 indicates premium valuation. High volatility (stability score 22/100) increases portfolio risk.

In summary, Annovis Bio, Inc. (ANVS) earns a Avoid rating with a composite score of 28.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ANVS stock.

Related Resources for ANVS Investors

Explore more research and tools: ANVS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ANVS head-to-head with peers: ANVS vs AZN, ANVS vs SLGL, ANVS vs VMD.